{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:10:47Z","timestamp":1791875447955,"version":"4.3.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Cardiotoxicity, manifest by reduced left ventricular ejection fraction (LVEF), is the most common reason for the premature discontinuation of trastuzumab. While permissive cardiotoxicity (where mild cardiotoxicity is accepted to enable ongoing trastuzumab) has been shown feasible, the longer-term outcomes are unknown. We aimed to study the intermediate-term clinical outcomes of patients who underwent permissive cardiotoxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We performed a retrospective cohort study of patients referred to the cardio-oncology service at McMaster University from 2016 to 2021 for LV dysfunction following trastuzumab administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifty-one patients underwent permissive cardiotoxicity. The median (25th-75th percentile) follow-up time from cardiotoxicity onset was 3 years (1.3-4 years). Forty-seven (92%) patients completed trastuzumab; 3 (6%) developed severe LV dysfunction or clinical heart failure (HF) while on trastuzumab and prematurely discontinued therapy. One discontinued trastuzumab by patient choice. At final follow-up after therapy completion, 7 (14%) patients still had mild cardiotoxicity, including 2 who had clinical heart failure and stopped trastuzumab early. Among those with recovered LV function, 50% had normalized LVEF or GLS by 6 and 3 months, respectively, after initial cardiotoxicity. There was no difference in characteristics between those who did or did not recover their LV function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Among patients exposed to permissive trastuzumab cardiotoxicity for HER2-positive breast cancer, 6% were unable to complete planned trastuzumab due to severe LV dysfunction or clinical HF. Although most patients recover their LV function after trastuzumab discontinuation or completion, 14% still have persistent cardiotoxicity by 3-year follow-up.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad086","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T01:32:35Z","timestamp":1682386355000},"page":"e712-e722","source":"Crossref","is-referenced-by-count":23,"title":["Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2080-5610","authenticated-orcid":false,"given":"Shijie","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Medicine, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8420-7628","authenticated-orcid":false,"given":"Filipe","family":"Cirne","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7942-6765","authenticated-orcid":false,"given":"Justin","family":"Chow","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Zereshkian","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Bordeleau","sequence":"additional","affiliation":[{"name":"Department of Oncology, Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhbinder","family":"Dhesy-Thind","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M","family":"Ellis","sequence":"additional","affiliation":[{"name":"Department of Oncology, Department of Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Som D","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Aghel","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl P","family":"Leong","sequence":"additional","affiliation":[{"name":"Population Health Research Institute and Department of Medicine, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"issue":"1","key":"2023090805111760900_CIT0001","first-page":"13","article-title":"Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers","volume":"1","author":"Mohan","year":"2018","journal-title":"Antib Ther"},{"issue":"16","key":"2023090805111760900_CIT0002","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2\u2013positive operable breast cancer","volume":"23","author":"Buzdar","year":"2005","journal-title":"JCO"},{"issue":"16","key":"2023090805111760900_CIT0003","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"2023090805111760900_CIT0004","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1634\/theoncologist.2019-0263","article-title":"Adjuvant trastuzumab therapy: can we balance efficacy and safety","volume":"24","author":"Barron","year":"2019","journal-title":"Oncologist."},{"key":"2023090805111760900_CIT0005","volume-title":"Product monograph","author":"Health Canada"},{"key":"2023090805111760900_CIT0006","author":"U.S. Food and Drug Administration","year":"2010"},{"issue":"1","key":"2023090805111760900_CIT0007","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3747\/co.2008.199","article-title":"Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group","volume":"15","author":"Mackey","year":"2008","journal-title":"Curr Oncol"},{"key":"2023090805111760900_CIT0008","author":"MHRA"},{"issue":"Epub","key":"2023090805111760900_CIT0009","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.08.001","article-title":"Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials","volume":"60","author":"Gyawali","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2023090805111760900_CIT0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40959-020-00081-9","article-title":"Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer","volume":"6","author":"Sardesai","year":"2020","journal-title":"Cardio-Oncol"},{"issue":"4","key":"2023090805111760900_CIT0011","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3747\/co.26.4631","article-title":"An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction","volume":"26","author":"Barron","year":"2019","journal-title":"Curr Oncol."},{"issue":"41","key":"2023090805111760900_CIT0012","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2023090805111760900_CIT0013","first-page":"ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","author":"Herrmann","year":"2021","journal-title":"Eur H J"},{"issue":"1","key":"2023090805111760900_CIT0014","first-page":"1","article-title":"Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial","volume":"1","author":"Leong","year":"2019","journal-title":"J Am Coll Cardiol Cardio Onc"},{"issue":"14","key":"2023090805111760900_CIT0015","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"2023090805111760900_CIT0016","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.breast.2011.12.012","article-title":"Epirubicin: Is it like doxorubicin in breast cancer? A clinical review","volume":"21","author":"Khasraw","year":"2012","journal-title":"The Breast"},{"issue":"1","key":"2023090805111760900_CIT0017","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0959-8049(93)90573-X","article-title":"A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer","volume":"29","author":"Levine","year":"1993","journal-title":"Eur J Cancer"},{"issue":"44","key":"2023090805111760900_CIT0018","doi-asserted-by":"crossref","first-page":"e5195","DOI":"10.1097\/MD.0000000000005195","article-title":"Risk factors of \u00adtrastuzumab-induced cardiotoxicity in breast cancer: a \u00admeta-analysis","volume":"95","author":"Jawa","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2023090805111760900_CIT0019","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","article-title":"Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer","volume":"18","author":"Tarantini","year":"2012","journal-title":"J Card Fail"},{"issue":"2","key":"2023090805111760900_CIT0020","first-page":"190","article-title":"Cardiac side effects of trastuzumab in breast cancer patients\u2014single center experiences","volume":"17","author":"Huszno","year":"2013","journal-title":"Contemp Oncol (Pozn)"},{"issue":"8","key":"2023090805111760900_CIT0021","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cardfail.2009.04.011","article-title":"\u00adTrastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study","volume":"15","author":"Guglin","year":"2009","journal-title":"J Card Fail"},{"issue":"1","key":"2023090805111760900_CIT0022","first-page":"37","article-title":"Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer","volume":"10","author":"Sato","year":"2019","journal-title":"Mol Cli Oncol"},{"issue":"31","key":"2023090805111760900_CIT0023","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","article-title":"Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by \u00adpaclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2\u2013positive breast cancer","volume":"30","author":"Romond","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10075","key":"2023090805111760900_CIT0024","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years\u2019 \u00adfollow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"The Lancet"},{"issue":"1","key":"2023090805111760900_CIT0025","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10549-019-05453-z","article-title":"A pooled analysis of the cardiac events in the trastuzumab adjuvant trials","volume":"179","author":"Azambuja","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"2023090805111760900_CIT0026","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s00392-019-01417-x","article-title":"Impacts of non-recovery of \u00adtrastuzumab-induced cardiomyopathy on clinical outcomes in patients with breast cancer","volume":"108","author":"Yoon","year":"2019","journal-title":"Clin Res Cardiol"},{"issue":"10","key":"2023090805111760900_CIT0027","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/echo.15190","article-title":"Immediate evaluation of global longitudinal strain at initiation of trastuzumab treatment in breast cancer patients","volume":"38","author":"Banke","year":"2021","journal-title":"Echocardiogr"},{"issue":"6","key":"2023090805111760900_CIT0028","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cardfail.2021.01.003","article-title":"Assessment of myocardial fibrosis using two-dimensional and three-dimensional speckle tracking echocardiography in dilated cardiomyopathy with advanced heart failure","volume":"27","author":"Wang","year":"2021","journal-title":"J Card Fail"},{"issue":"7","key":"2023090805111760900_CIT0029","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/ejechocard\/jer318","article-title":"Clinical significance of global two-dimensional strain as a surrogate parameter of myocardial fibrosis and cardiac events in patients with hypertrophic cardiomyopathy","volume":"13","author":"Saito","year":"2012","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"11","key":"2023090805111760900_CIT0030","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.cjco.2021.06.019","article-title":"Pertuzumab cardiotoxicity in patients with HER2-positive cancer: a systematic review and meta-analysis","volume":"3","author":"Alhussein","year":"2021","journal-title":"CJC Open"},{"issue":"Epub","key":"2023090805111760900_CIT0031","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2018.12.022","article-title":"Safety of trastuzumab \u00ademtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1","volume":"109","author":"Montemurro","year":"2019","journal-title":"Eur J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/9\/e712\/51436874\/oyad086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/9\/e712\/51436874\/oyad086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:11:48Z","timestamp":1694149908000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/9\/e712\/7140381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,4,24]]},"published-print":{"date-parts":[[2023,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad086","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,4,24]]}}}